Pharmacologic management of Alzheimer disease
- PMID: 18330411
- DOI: 10.1097/01376517-200802000-00009
Pharmacologic management of Alzheimer disease
Abstract
Although the diagnosis of AD can be devastating, treatment options exist that can slow the disease's progression and allow patients to continue performing ADLs, thereby improving the quality of life for both patient and caregiver. Research is ongoing, and it is estimated by the Alzheimer's Association that finding a treatment that could delay onset by only 5 years could reduce the number of individuals with AD by nearly 50% over the next 50 years (Alzheimer's Association, 2007). Although pharmacotherapy is not yet a cure, it does remain an important part of a total approach to caring for patients and families affected by AD.
Similar articles
-
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. J Alzheimers Dis. 2014. PMID: 24662102
-
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.Prescrire Int. 2006 Jun;15(83):103-6. Prescrire Int. 2006. PMID: 16764099
-
[Medical treatment of Alzheimer's disease].Ugeskr Laeger. 2006 Oct 2;168(40):3424-9. Ugeskr Laeger. 2006. PMID: 17032609 Review. Danish.
-
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Int Psychogeriatr. 2009 Oct;21(5):813-24. doi: 10.1017/S1041610209990354. Epub 2009 Jun 19. Int Psychogeriatr. 2009. PMID: 19538824
-
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.Expert Opin Drug Saf. 2004 Sep;3(5):425-40. doi: 10.1517/14740338.3.5.425. Expert Opin Drug Saf. 2004. PMID: 15335298 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical